Androgen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxA New Compound Looks Promising for Bone Metastasis
/0 Comments/in Not PCa related, Preclinical Research/by MaxPreclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer
/0 Comments/in Preclinical Research/by MaxHyperthermia: Where Are We With Solid Tumors?
/0 Comments/in Hyperthermia, Preclinical Research/by MaxNew Anti-Metastatic Agent Adhibin Discovered: A Potential Game Changer in Cancer Treatment
/0 Comments/in Preclinical Research/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/0 Comments/in Artificial Intelligence, Preclinical Research/by MaxCRISPR Strikes Again: Fat Cells Starve Tumors,A Revolutionary Approach to Cancer Treatment
/0 Comments/in CRISPR, Preclinical Research/by MaxBatiraxcept’s Potential in Combating Prostate Cancer Bone Metastases
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025